Variant · Expression
DLL3 Expression
CI-VAR-00001043Explore in graph →CIViC 2209
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27932068
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Small Cell Carcinoma2 | ||||||||
| DLL3 Expression | Rovalpituzumab Tesirine | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID591974 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma received at least one dose of rovalpituzumab tesirine in a phase 1 trial. 11 (18%) of 60 assessable patients … (full text at CIViC) PMID 27932068 · Rudin et al., 2017 · Open in CIViC | civic |
| DLL3 Expression | Rovalpituzumab Tesirine | Predictive | B | Does Not Support Sensitivity Response | 4 | submitted | EID7764In a phase II trial, patients with DLL3-expressing small cell lung carcinoma were treated with rovalpituzumab tesirine. Only patients with 1% or more tumor cells expressing DLL3 were enrolled. In this… (full text at CIViC) PMID 31506387 · Morgensztern et al., 2019 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available